Cetera Investment Advisers
TGTX icon

Cetera Investment Advisers’s TG Therapeutics TGTX Stock Holding History

Cetera Investment Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.22M Buy
76,883
+6,353
+9% +$260K ﹤0.01% 1755
2026
Q1 		$2.34M Sell
70,530
-5,834
-8% -$174K ﹤0.01% 2149
2025
Q4 		$2.28M Buy
76,364
+7,009
+10% +$229K ﹤0.01% 2104
2025
Q3 		$2.51M Buy
69,355
+21,727
+46% +$716K ﹤0.01% 1982
2025
Q2 		$1.71M Buy
47,628
+311
+0.7% +$11.6K ﹤0.01% 1961
2025
Q1 		$1.87M Sell
47,317
-4,882
-9% -$164K ﹤0.01% 1800
2024
Q4 		$1.57M Sell
52,199
-512
-1% -$14.7K ﹤0.01% 1823
2024
Q3 		$1.23M Sell
52,711
-714
-1% -$15.6K ﹤0.01% 1974
2024
Q2 		$950K Sell
53,425
-9,652
-15% -$154K ﹤0.01% 2109
2024
Q1 		$959K Buy
63,077
+26,693
+73% +$425K ﹤0.01% 2101
2023
Q4 		$621K Sell
36,384
-7,017
-16% -$81.6K 0.01% 1377
2023
Q3 		$363K Buy
43,401
+2,634
+6% +$36.7K ﹤0.01% 1600
2023
Q2 		$1.01M Buy
40,767
+3,593
+10% +$92.8K 0.01% 1056
2023
Q1 		$559K Buy
37,174
+18,605
+100% +$283K ﹤0.01% 1363
2022
Q4 		$220K Sell
18,569
-255
-1% -$1.85K ﹤0.01% 1851
2022
Q3 		$111K Buy
18,824
+200
+1% +$1.31K ﹤0.01% 1573
2022
Q2 		$79K Buy
18,624
+1,311
+8% +$8.19K ﹤0.01% 1751
2022
Q1 		$165K Sell
17,313
-4,346
-20% -$50.3K ﹤0.01% 1752
2021
Q4 		$412K Buy
21,659
+2,914
+16% +$75.7K 0.01% 1300
2021
Q3 		$624K Buy
18,745
+6,246
+50% +$193K 0.01% 1011
2021
Q2 		$485K Buy
+12,499
New +$491K 0.01% 1139

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Cetera Investment Advisers's TGTX Position: Q2 2026 in Review

Cetera Investment Advisers increased its TG Therapeutics (TGTX) stake by 9% in Q2 2026, buying an estimated $260K and bringing the position to 76,883 shares worth $4.22M. The position accounts for ﹤0.01% of the portfolio, ranked #1755.

Cetera Investment Advisers first reported a position in TGTX in Q2 2021 and has held it in 21 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Cetera Investment Advisers held 76,883 shares of TG Therapeutics worth $4.22M as of Q2 2026.
  • Cetera Investment Advisers bought 6,353 TG Therapeutics shares in Q2 2026, an estimated $260K.
  • TG Therapeutics made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #1755 holding.
  • Cetera Investment Advisers first reported a position in TG Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.